The ubiquitin-poteasome system plays essential roles in presenting an 8-mer CTL epitope expressed in APC to corresponding CD8+ T cells

International Immunology

Volumn 18, Issue 5, 2006, Pages 679-687

  Duan, Xuefeng ^a   Hisaeda, Hajime ^a   Shen, Jianying ^a   Tu, Liping ^a   Imai, Takashi ^a   Chou, Bin ^a   Murata, Shigeo ^b   Chiba, Tomoki ^b   Tanaka, Keiji ^b   Fehling, Hans Jörg ^c   Koga, Takaomi ^a   Sueishi, Katsuo ^a   Himeno, Kunisuke ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^c UNIVERSITY OF ULM   (Germany)

Author keywords

Antigen presentation; Ubiquitin fusion degradation pathway

Indexed keywords

CANCER ANTIBODY; MUTANT PROTEIN; PROTEASOME; TUMOR CELL VACCINE; UBIQUITIN; DNA VACCINE; EPITOPE; GAMMA INTERFERON; LMP7 PROTEIN; MULTIENZYME COMPLEX; MUT 1 PEPTIDE; OLIGOPEPTIDE; PROTEIN; PSME1 PROTEIN, MOUSE; PSME2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME DEGRADATION; ENZYME POLYMORPHISM; EXPRESSION VECTOR; FEMALE; GENE THERAPY; IN VITRO STUDY; IN VIVO STUDY; LEWIS CARCINOMA; METASTASIS INHIBITION; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; VACCINE PRODUCTION; ANIMAL; BIOLISTIC TRANSFORMATION; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; CELL STRAIN COS1; CERCOPITHECUS; CYTOTOXIC T LYMPHOCYTE; ENZYMOLOGY; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE MUTANT;

ANIMALS; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; BIOLISTICS; CARCINOMA, LEWIS LUNG; CERCOPITHECUS AETHIOPS; COS CELLS; EPITOPES, T-LYMPHOCYTE; FEMALE; INTERFERON TYPE II; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MULTIENZYME COMPLEXES; OLIGOPEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; UBIQUITIN; VACCINES, DNA;

EID: 33646875978     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxl005     Document Type: Article

References (60)

1. Mandelboim, O., Berke, G., Fridkin, M., Feldman, M., Eisenstein, M. and Eisenbach, L. 1994. CTL induction by a tumor associated antigen octapeptide derived from a murine lung carcinoma. Nature 369:67.
2. Boon, T., Gerottini, C. J., Van Der Eynde, B., Van Der Brugenn, P. and Van Pel, A. 1994. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12:337.
3. Boon, T. 1995. Tumor antigens and perspectives for cancer immunotherapy. Immunologist 3:262.
4. Cox, A. L., Skipper, J., Chen, Y. et al. 1994. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716.
5. Rabinovich, N. R., McInnes, P., Klein, D. L. and Hall, B. F. 1994. Vaccine technologies: View to the future. Science 265:1401.
6. Mocellin, S., Mandruzzato, S., Bronte, V., Lise, M. and Nitti, D. 2004. Part I: Vaccines for solid tumours. Lancet Oncol. 5:681.
7. Engelhard, V. H., Bullock, T. N., Colella, T. A., Sheasley, S. L. and Mullins, D. W. 2002. Antigens derived from melanocyte differentiation proteins: Self-tolerance, autoimmunity, and use for cancer immunotherapy. Immunol. Rev. 188:136.
8. Ward, S., Casey, D., Labarthe, M. C. et al. 2002. Immunotherapeutic potential of whole tumour cells. Cancer Immunol. Immunother. 51:351.
9. Jaffee, E. M., Hruban, R. H., Biedrzychi, B. et al. 2001. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immune activation. J. Clin. Oncol. 19:145.
10. Dranoff, G. 2002. GM-CSF-based cancer vaccines. Immunol. Rev. 188:147.
11. Song, K., Chang, Y. and Prud'homme, G. J. 2000. Regulation of T-helper-1 versus T-helper-2 activity and enhancement of tumor immunity by combined DNA-based vaccination and nonviral cytokine gene transfer. Gene Ther. 7:481.
12. Song, K., Chang, Y. and Prud'homme, G. J. 2000. IL-12 plasmid-enhanced DNA vaccination against carcinoembryonic antigen (CEA) studied in immune-gene knockout mice. Gene Ther. 7:1527.
13. Chakrabarti, R., Chang, Y., Song, K. and Pru'dhomme, G. J. 2004. Plasmids encoding membrane-bound IL-4 or IL-12 strongly costimulate DNA vaccination against carcinoembryonic antigen (CEA). Vaccine 22:1199.
14. Amici, A., Smorlesi, A., Noce, G. et al. 2000. DNA vaccination with full-length or truncated neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Gene Ther. 7:703.
15. Di Carlo, E., Rovero, S., Boggio, K. et al. 2001. Inhibition of mammary carcinogenesis by systemic interleukin 12 or p185neu DNA vaccination in Her-2/neu transgenic BALB/c mice. Clin. Cancer Res. 7:830s.
16. Rovero, S., Boggio, K., Carlo, E. D. et al. 2001. Insertion of the DNA for the 163-171 peptide of (L1beta enables a DNA vaccine encoding p185 (neu) to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c mice. Gene Ther. 8:447.
17. Piechocki, M. P., Ho, Y. S., Pilon, S. and Wei, W. Z. 2003. Human ErbB-2 (Her-2) transgenic mice: A model system for testing Her-2 based vaccines. J. Immunol. 171:5787.
18. Pilon, S. A., Piechocki, M. P. and Wei, W. Z. 2001. Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody. J. Immunol. 167:3201.
19. Pasquini, S., Peralta, S., Missiaglia, E., Carta, L. and Lemoine, N. R. 2002. Prime-boost vaccines encoding an intracellular idio-type/GM-CSF fusion protein induce protective cell-mediated immunity in murine pre-B cell leukemia. Gene Ther. 9:503.
20. Timmerman, J. M., Singh, G., Hermanson, G. et al. 2002. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res. 62:5845.
21. Hawkins, W. G., Gold, J. S., Dyall, R. et al. 2000. Immunization with DNA coding for gp100 results in CD4 T -cell independent antitumor immunity. Surgery 128:273.
22. Rakhmilevich, A. L., Imboden, M., Hao, Z. et al. 2001. Effective particle-mediated vaccination against mouse melanoma by coadministration of plasmid DNA encoding gp100 and granulocyte-macrophage colony-stimulating factor. Clin. Cancer Res. 7:952.
23. Kim, J. J., Yang, J. S., Dang, K., Manson, K. H. and Weiner, D. B. 2001. Engineering enhancement of immune responses to DNA-based vaccines in prostate cancer model in rhesus macaques through the use of cytokine gene adjuvants. Clin. Cancer Res. 7:882s.
24. Tanaka, K. and Kasahara, M. 1998. The MHC class I ligand-generating system: Roles of immunoproteasomes and the interferon-gamma-inducible proteasome activator PA28. Immunol. Rev. 163:161.
25. Rock, K. L., York, I. A., Saric, T. and Goldberg, A. L. 2002. Protein degradation and the generation of MHC class I-presented peptides. Adv. Immunol. 80:1.
26. Kloetzel, P. M. 2001. Antigen processing by the proteasome. Nat. Rev. Mol. Cell Biol. 2:179.
27. Johnson, E. S., Ma, P. C., Ota, I. M. and Varshavsky, A. 1995. A proteolytic pathway that recognizes ubiquitin as a degradation signal. J. Biol. Chem. 270:17442.
28. Glickman, M. H. and Ciechanover, A. 2002. The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction. Physiol. Rev. 82:373.
29. Butt, T. R., Khan, M. I., Marsh, J., Ecker, D. J. and Crooke, S. T. 1988. Ubiquitin-metallothionein fusion protein expression in yeast. A genetic approach for analysis of ubiquitin function. J. Biol. Chem. 263:16364.
30. Johnson, E. S., Bartel, B., Seufert, W. and Varshavsky, A. 1992. Ubiquitin as a degradation signal. EMBO J. 11:497.
31. Murata, S., Udono, H., Tanahashi, N. et al. 2001. Immunoproteasome assembly and antigen presentation in mice lacking both PA28alpha and PA28beta. EMBO J. 20:5898.
32. Zhang, M., Obata, C., Hisaeda, H. et al. 2005. A novel DNA vaccine based on the ubiquitin-proteasome pathway targeting 'self'-antigen expressed in melanoma/melanocyte. Gene Ther. 12:1049.
33. Xiang, R., Lode, H. N., Chao, T. H. et al. 2000. An autologous oral DNA vaccine protects against murine melanoma. Proc. Natl Acad. Sci. USA 97:5492.
34. Wilson, C. C., McKinney, D., Anders, M. et al. 2003. Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1. J. Immunol. 171:5611.
35. Bartholdy, C., Stryhn, A., Hansen, N. J., Buus, S. and Thomsen, A. R. 2003. Incomplete effector/memory differentiation of antigen-primed CD8+ T cells in gene gun DNA-vaccinated mice. Eur. J. Immunol. 33:1941.
36. Bartholdy, C., Olszewska, W., Stryhn, A., Thomsen, A. R. and Openshaw, P. J. 2004. Gene-gun DNA vaccination aggravates respiratory syncytial virus-induced pneumonitis. J. Gen. Virol. 85(Pt 10):3017.
37. Rasmussen, A. B., Zocca, M. B., Bonefeld, C. M. et al. 2004. Proteasomal targeting and minigene repetition improve cell-surface presentation of a transfected, modified melanoma tumour antigen. Scand. J. Immunol. 59:220.
38. Mandelboim, O., Bar-Haim, E., Vadai, E., Fridkin, M. and Eisenbach, L. 1997. Identification of shared tumor-associated antigen peptides between two spontaneous lung carcinomas. J. Immunol. 159:6030.
39. Fehling, H. J., Swat, W., Laplace, C. et al. 1994. MHC class I expression in mice lacking the proteasome subunit LMP-7. Science 265:1234.
40. Nishitani, M. A., Sakai, T., Ishii, K. et al. 2002. A convenient cancer vaccine therapy with in vivo transfer of interleukin 12 expression plasmid using gene gun technology after priming with irradiated carcinoma cells. Cancer Gene Ther 9:156.
41. Sakai, T, Hisaeda, H., Nakano, Y. et al. 2000. Gene gun-mediated delivery of an interleukin-12 expression plasmid protects against infections with the intracellular protozoan parasites Leishmania major and Trypanosoma cruzi in mice. Immunology 99:615.
42. Sakai, T., Hisaeda, H., Nakano, Y. et al. 2003. Gene gun-based co-immunization of merozoite surface protein-1 cDNA with IL-12 expression plasmid confers protection against lethal Plasmodium yoelii in A/J mice. Vaccine 21:1432.
43. Matzinger, P. 1991. The JAM test. A simple assay for DNA fragmentation and cell death. J. Immunol. Methods 145:185.
44. Inaba, K., Young, J. W. and Steinman, R. M. 1987. Direct activation of CD8+ cytotoxic T lymphocytes by dendritic cells. J. Exp. Med. 166:182.
45. Steitz, J., Bruck, J., Gambotto, A., Knop, J. and Tuting, T. 2002. Genetic immunization with a melanocytic self-antigen linked to foreign helper sequences breaks tolerance and induces autoimmunity and tumor immunity. Gene Ther. 9:208.
46. Leitner, W. W., Hwang, L. N., deVeer, M. J. et al. 2003. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat. Med. 9:33.
47. Koegl, M., Hoppe, T., Schlenker, S., Ulrich, H. D., Mayer, T. U. and Jentsch, S. 1999. A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell 96:635.
48. Richly, H., Rape, M., Braun, S., Rumpf, S., Hoege, C. and Jentsch, S. 2005. A series of ubiquitin binding factors connects CDC48/p97 to substrate multiubiquitylation and proteasomal targeting. Cell 120:73.
49. Kloetzel, P. M. and Ossendorp, F. 2004. Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr. Opin. Immunol. 16:76.
50. Driscoll, J., Brown, M. G., Finley, D. and Monaco, J. J. 1993. MHC-linked LMP gene products specifically alter peptidase activities of the proteasome. Nature 365:262.
51. Gaczynska, M., Rock, K. L. and Goldberg, A. L. 1993. Γ-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. Nature 365:264.
52. Aki, M., Shimbara, N., Takashina, M. et al. 1994. Interferon-γ induces different subunit organizations and functional diversity of proteasomes. J. Biochem. 115:257.
53. Sijts, A., Zaiss, D. and Kloetzel, P. M. 2001. The role of the ubiquitin-proteasome pathway in MHC class I antigen processing: implications for vaccine design. Curr Mol. Med. 1:665.
54. Griffin, T. A., Nandi, D., Cruz, M. et al. 1998. Immunoproteasome assembly: Cooperative incorporation of interferon gamma (IFN-gamma)-inducible subunits. J. Exp. Med. 187:97.
55. Groettrup, M., Soza, A., Eggers, M. et al. 1996. A role for the proteasome regulator PA28alpha in antigen presentation. Nature 381:166.
56. Rechsteiner, M., Realini, C. and Ustrell, V. 2000. The proteasome activator 11 S REG (PA28) and class I antigen presentation. Biochem. J. 345(Pt 1):1.
57. Coux, O., Tanaka, K. and Goldberg, A. L. 1996. Structure and functions of the 20S and 26S proteasomes. Annu. Rev. Biochem. 65:801.
58. Dick, T. P., Ruppert, T., Groettrup, M. et al. 1996. Coordinated dual cleavages induced by the proteasome regulator PA28 lead to dominant MHC ligands. Cell 86:253.
59. Zhang, M., Ishii, K., Hisaeda, H. et al. 2004. Ubiquitin-fusion degradation pathway plays an indispensable role in naked DNA vaccination with a chimeric gene encoding a syngeneic cytotoxic T lymphocyte epitope of melanocyte and green fluorescent protein. Immunology 112:567.
60. Koehler, A., Cascio, P., Legget, D. S., Woo, K. M., Goldberg, A. L. and Finley, D. 2001. The axial channel of the proteasome core particle is gated by the Rpt2 ATPase and controls both substrate entry and product release. Mol. Cell 7:1143.